Which of the following drug-receptor target pairings are correctly matched? 1. Trastuzumab — HER2 receptor 2. Sunitinib — HER1 (EGFR) 3. Gefitinib — HER1 (EGFR)

1. A

   A. Only 1 is correct

2. B

   B. 1 and 3 are correct

3. C

   C. 2 and 3 are correct

4. D

   D. All are correct

Appeared in: INI-CET EXAM -2026

Explanation

• This option correctly identifies that statements 1 and 3 are accurate pairings.
• Statement 1 is correct: Trastuzumab is a monoclonal antibody that specifically binds to and inhibits the HER2 receptor, a key therapy for HER2-positive cancers.
• Statement 3 is correct: Gefitinib is a tyrosine kinase inhibitor that targets the HER1 (EGFR) receptor, used for cancers with specific EGFR mutations, such as non-small cell lung cancer.

Why Other Options Were Wrong

• Option A: This option is incomplete. While statement 1 (Trastuzumab-HER2) is correct, statement 3 (Gefitinib-HER1) is also a correct pairing.
• Option C: This option is incorrect because statement 2 (Sunitinib-HER1) is false. Sunitinib's primary targets are VEGFR and PDGFR, not HER1 (EGFR).
• Option D: This option is incorrect because statement 2 (Sunitinib-HER1) is a false pairing. Not all the listed pairings are correct.

Related Visual

Clinical Relevance

• Nursing practice connection: Knowing Targeted Cancer Therapy and Drug-Receptor Specificity helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
• Nurses administering targeted therapies must know the specific drug target to anticipate and manage unique side effects. For example, cardiotoxicity is a major concern with the HER2 inhibitor Trastuzumab, while skin rash and diarrhea are common with EGFR inhibitors like Gefitinib.
• Patient education is a key nursing role. Patients need to understand that targeted therapies are different from traditional chemotherapy and have distinct side effect profiles and administration schedules.
• Pre-treatment testing for biomarkers (like HER2 status or EGFR mutations) is essential for these drugs to be effective. Nurses play a role in coordinating care and ensuring test results are available before starting therapy.

How to Approach the Question

• First, recognize this is a multiple-statement question where you must evaluate the accuracy of each numbered item.
• Address each statement individually. Recall or use your knowledge of pharmacology to determine if the drug-receptor pairing is correct.
• Statement 1: Trastuzumab is famously linked to the HER2 receptor. Mark this as 'Correct'.
• Statement 2: Sunitinib is a multi-kinase inhibitor, primarily known for its anti-angiogenic effects by targeting VEGFR and PDGFR, not EGFR/HER1. Mark this as 'Incorrect'.
• Statement 3: Gefitinib is a classic example of an EGFR (HER1) tyrosine kinase inhibitor. Mark this as 'Correct'.
• Finally, review the options to find the one that matches your evaluation: '1 and 3 are correct'.

Concept Tested & Keywords

• Concept Tested: Targeted Cancer Therapy and Drug-Receptor Specificity
• Stem keywords: Trastuzumab, Sunitinib, Gefitinib, HER2 receptor, HER1 (EGFR), drug-receptor target
• Lead-in keywords: correctly matched
• Negative lead-in flag: false

Question ID

Qm42gxdhnS6EUIZ5PdSq_o

Copy ID

Reference Book

E6 Pharmacology Katzung 16e p. 1500-1502

E6 Medicine Harrison 22e Part 1 p. 577-579